Clinical bottom line
Emerging therapies targeting neutrophil subsets represent a promising frontier in the management of autoimmune vasculitis, particularly anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Current evidence suggests that modulating neutrophil function and survival may improve disease control and reduce relapse rates. However, these approaches remain largely experimental, with limited clinical trial data on long-term efficacy and safety. Clinicians should remain informed about ongoing developments but continue to rely on established maintenance therapies until further validation is available.
What the evidence shows
Neutrophils play a central pathogenic role in autoimmune vasculitis, especially in AAV, where aberrant activation and priming of neutrophil subsets contribute to vascular inflammation and tissue damage. Recent advances have focused on selectively targeting these neutrophil populations to modulate disease activity without broadly suppressing immunity.
Odobasic et al. (2021) provide a comprehensive review of emerging cellular therapies for anti-myeloperoxidase vasculitis, highlighting strategies such as neutrophil depletion, inhibition of neutrophil extracellular trap (NET) formation, and modulation of neutrophil lifespan. These approaches aim to reduce the pathogenic neutrophil-mediated injury while preserving host defense.
A network meta-analysis by Bellos et al. (2021) compared maintenance therapies for ANCA small vessel vasculitis but did not specifically evaluate neutrophil-targeted agents, reflecting the nascent stage of clinical application for these therapies. Nonetheless, the study underscores the unmet need for safer, more effective maintenance options, which neutrophil-targeted therapies may fulfill in the future.
Additional immunopharmacology reviews (2025) discuss novel agents that interfere with neutrophil activation pathways, such as inhibitors of signaling molecules involved in neutrophil priming and adhesion. These agents are in preclinical or early clinical development, with preliminary data suggesting potential benefits in autoimmune disease models.
Caveats and uncertainty
The clinical evidence for neutrophil subset-targeted therapies in autoimmune vasculitis remains limited and largely preclinical or early phase. Most data derive from mechanistic studies or small cohorts rather than large randomized controlled trials. Safety profiles are incompletely characterized, particularly regarding infection risk and long-term immunosuppression.
Heterogeneity in neutrophil subsets and their dynamic roles in inflammation complicate therapeutic targeting. There is a risk that broad neutrophil depletion could impair host defense against infections. Furthermore, the optimal timing, dosing, and patient selection criteria for these therapies are not yet established.
Current standard-of-care maintenance therapies, including rituximab and azathioprine, have well-documented efficacy and safety profiles, making it challenging to justify early adoption of unproven neutrophil-targeted agents outside clinical trials.
How this may change practice
As clinical trials mature, neutrophil subset-targeted therapies may offer a novel mechanism to improve disease control in refractory or relapsing autoimmune vasculitis, potentially reducing reliance on broad immunosuppression and its associated toxicities. Biomarker-guided approaches to identify patients with neutrophil-driven pathology could personalize therapy.
Clinicians should monitor emerging data from ongoing studies and consider referral of eligible patients to clinical trials investigating these agents. Integration of neutrophil-targeted therapies into clinical practice will require robust evidence demonstrating superior efficacy, safety, and cost-effectiveness compared to current standards.
In the interim, maintaining vigilance for infection risk and disease relapse remains paramount when managing autoimmune vasculitis, with established therapies continuing as the mainstay of treatment.